Insulin Therapy
Insulin therapy is a hormone-replacement treatment in which exogenous insulin is administered to lower and stabilize blood glucose in people whose endogenous insulin secretion or action is insufficient.
Insulin therapy is a hormone-replacement treatment in which exogenous insulin is administered to lower and stabilize blood glucose in people whose endogenous insulin secretion or action is insufficient. In clinical use since the early 1920s, it is the indispensable, lifelong treatment for type 1 diabetes, where autoimmune destruction of pancreatic beta cells abolishes endogenous secretion, and it is added in advanced type 2 diabetes when lifestyle measures, metformin, SGLT2 inhibitors, GLP-1 receptor agonists such as semaglutide, and other non-insulin agents no longer maintain adequate glycemic control. It is also used to manage drug-induced hyperglycemia, including the hyperglycemia caused by Phosphatidylinositol 3-kinase (PI3K) inhibitors such as alpelisib in oncology. Because the therapeutic goal is to reproduce a physiological secretion pattern, formulations are grouped by kinetics: rapid-acting analogs given as mealtime boluses or delivered by pump, and intermediate- or long-acting basal preparations. Dosing is titrated against glycemic monitoring, and the main treatment-limiting harm is hypoglycemia, alongside weight gain.
Therapeutically administered insulin acts through the same pathway as the native hormone, binding the insulin receptor — a receptor tyrosine kinase — and initiating signaling that drives glucose uptake into skeletal muscle and adipose tissue, suppresses hepatic glucose production, and promotes glycogen, lipid, and protein synthesis. In obesity-related type 2 diabetes this signaling is blunted by insulin resistance, characterized by reduced insulin-stimulated glucose uptake, intramuscular triacylglycerol accumulation, and mitochondrial dysfunction; resistance interacts with adipose-derived signals such as leptin and with cellular energy sensing through AMP-activated protein kinase, and progression to diabetes depends on whether beta-cell secretory compensation keeps pace with falling sensitivity. insulin signaling also has non-metabolic consequences: it shapes CD4+ effector memory T-cell metabolism and phenotype through epigenetic mechanisms, a link observed in autoimmune settings such as rheumatoid arthritis, and hyperinsulinemia is associated with an altered inflammatory milieu including Interleukin-6 (IL-6) and C-C motif chemokine ligand 2. Current pharmaceutical development focuses on automated (closed-loop) insulin delivery systems paired with continuous glucose monitoring, on formulation stability and oligomerization behavior, which govern absorption kinetics, and on alternative routes — oral, sublingual, transdermal, and ocular — together with glucose-responsive delivery systems intended to release insulin in proportion to ambient glucose.
Where the papers sit
21 papers from the last 6 months study Insulin Therapy directly · updated from PubMed 12 Oct 2026
Study type 2 clinical trials · 3 observational · 8 human data · 6 preclinical · 2 unclassified
Themes 4 themes
-
Diabetes Treatment Outcomes
Diabetes care research spans insulin therapy, metformin, glycemic control, insulin sensitivity, access barriers, and quality of life. Real-world studies compare insulin with non-insulin treatment while tracking renal function and outcomes after acute ischemic stroke. Genetic risk scores are being used to connect prediabetes with type 2 diabetes pathophysiology, while alpelisib-associated hyperglycemia highlights treatment-related metabolic toxicity. RA immune-cell biology and medication-access studies broaden the set beyond one shared clinical question.
7 papers · 33.3%
-
Glucose–Insulin Physiology
Glucose and insulin studies emphasize heterogeneous postprandial responses, early secretory defects, and the influence of obesity and body composition. One-hour plasma glucose and combined amino-acid and glucose challenges are being evaluated as markers of insulin and GLP-1 secretion. Vagal neuronal nitric oxide synthase 1 signaling is implicated in suppressed insulin release in obesity. Needle-free delivery and high-field ion analysis appear as largely separate technical strands, leaving the cluster without one coherent research direction.
6 papers · 28.6%
-
Insulin Delivery Technologies
Closed-loop insulin delivery is moving toward tighter glycemic control, while injectable hydrogels and microneedles seek longer or less invasive administration. Fully closed-loop systems are being compared with standard therapy using continuous glucose monitoring, with diabetic ketoacidosis and long-term utility remaining important endpoints. Eye-drop stability and sublingual or transdermal delivery address alternatives to injections. Budgetary impact remains central to adoption in type 1 diabetes.
5 papers · 23.8%
-
Insulin Protein Stability
Insulin and related peptide therapeutics are being examined through their aggregation, oligomerization, and interactions with supramolecular chaperones. Formulation work favors rapid molecular-mass assessment to characterize therapeutic protein states. Cellular studies ask whether insulin activates the unfolded protein response in muscle and whether obesity or type 2 diabetes changes that response. The common goal is to link protein structure and stability with therapeutic performance, but no single intervention dominates.
3 papers · 14.3%
Papers
The 21 papers from the last 6 months that study Insulin Therapy directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Diabetes Treatment Outcomes (7)
- Global and Partitioned Polygenic Risk Scores: Associations With Pathophysiology and Incidence of Type 2 Diabetes in People With Prediabetes. Diabetes · 22 Jun 2026 PMID 42330299
- Insulin enables acquisition of the IL7R+ memory phenotype in PD1+ T cells in RA tissues. Cell death & disease · 25 May 2026 PMID 42185247
- Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 20 May 2026 PMID 42159385
- National trends and comparative outcomes of insulin versus non-insulin therapy in acute ischemic stroke patients treated with mechanical thrombectomy: a retrospective cohort study using the national inpatient sample. Neurosurgical review · 19 May 2026 PMID 42156589
- Evaluating effect of Insulin therapy on Quality-of-life among Type 2 Diabetes Patients in Tertiary Care Hospitals: Observational Study from South Asian Region. La Clinica terapeutica · 28 Apr 2026 PMID 42047131
- When the system fails: Barriers to type 1 diabetes medication access and the emergent role of social media support. Diabetic medicine : a journal of the British Diabetic Association · 17 Apr 2026 PMID 41996632
- Pharmacological treatment patterns, factors associated with glycemic control, and renal function parameters in a real-world cohort of Hispanic adults with type 2 diabetes. Biomedical reports · 16 Apr 2026 PMID 41987878
Glucose–Insulin Physiology (6)
- Vagal activation inhibits insulin release through neuronal nitric oxide synthase in obese male mice. Science signaling · 26 May 2026 PMID 42189938
- The 1-hour plasma glucose as a specific marker for early-phase insulin secretory defects in young adults with obesity. Diabetes research and clinical practice · 25 May 2026 PMID 42184890
- Heterogeneity in postprandial glucose-insulin and triacylglycerol dynamics and associations with plasma metabolome and body composition in obesity. American journal of physiology. Endocrinology and metabolism · 21 May 2026 PMID 42166654
- Analyses of Individual Singly Charged Ions Using a High-Field Orbitrap Analyzer. Analytical chemistry · 12 May 2026 PMID 42117381
- Combination amino acids and glucose effects on insulin and GLP-1 secretion. The Biochemical journal · 22 Apr 2026 PMID 42017410
- Microfluidic jet injections enable precise needle-free delivery of insulin and liposomes into human ex vivo skin. International journal of pharmaceutics · 20 Apr 2026 PMID 42009147
Insulin Delivery Technologies (5)
- Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes. Diabetes technology & therapeutics · 1 Jul 2026 PMID 42381171
- Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol. BMJ open · 19 May 2026 PMID 42156154
- pH-Responsive Injectable Polyethylene Glycol and Dopamine-Grafted Chitosan Hydrogel for Sustained Insulin Release for Better Diabetic Treatment. ACS applied bio materials · 18 May 2026 PMID 42148601
- FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery. Drug delivery · 12 May 2026 PMID 42118678
- Long-term stability of insulin eye drops in three different vehicles. Journal of pharmaceutical sciences · 17 Apr 2026 PMID 41997424
Insulin Protein Stability (3)
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- The unfolded protein response and its activation by insulin in muscle are not altered by obesity or type 2 diabetes. Clinical science (London, England : 1979) · 22 Apr 2026 PMID 42017540
- Exploring the Holdase Activity of Supramolecular Chaperones with Amyloid-Forming Peptides and Insulin. Biomacromolecules · 16 Apr 2026 PMID 41988752
By study type
Clinical trials (2)
- Global and Partitioned Polygenic Risk Scores: Associations With Pathophysiology and Incidence of Type 2 Diabetes in People With Prediabetes. Diabetes · 22 Jun 2026 PMID 42330299
- Assessing the efficacy, safety and utility of fully closed-loop insulin delivery compared to standard insulin therapy with a continuous glucose monitor in adults with type 2 diabetes (COYOTE study): a randomised parallel study protocol. BMJ open · 19 May 2026 PMID 42156154
Observational studies and case reports (3)
- National trends and comparative outcomes of insulin versus non-insulin therapy in acute ischemic stroke patients treated with mechanical thrombectomy: a retrospective cohort study using the national inpatient sample. Neurosurgical review · 19 May 2026 PMID 42156589
- Evaluating effect of Insulin therapy on Quality-of-life among Type 2 Diabetes Patients in Tertiary Care Hospitals: Observational Study from South Asian Region. La Clinica terapeutica · 28 Apr 2026 PMID 42047131
- The unfolded protein response and its activation by insulin in muscle are not altered by obesity or type 2 diabetes. Clinical science (London, England : 1979) · 22 Apr 2026 PMID 42017540
Human data, design not indexed (8)
- Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 Diabetes. Diabetes technology & therapeutics · 1 Jul 2026 PMID 42381171
- Insulin enables acquisition of the IL7R+ memory phenotype in PD1+ T cells in RA tissues. Cell death & disease · 25 May 2026 PMID 42185247
- The 1-hour plasma glucose as a specific marker for early-phase insulin secretory defects in young adults with obesity. Diabetes research and clinical practice · 25 May 2026 PMID 42184890
- Heterogeneity in postprandial glucose-insulin and triacylglycerol dynamics and associations with plasma metabolome and body composition in obesity. American journal of physiology. Endocrinology and metabolism · 21 May 2026 PMID 42166654
- Microfluidic jet injections enable precise needle-free delivery of insulin and liposomes into human ex vivo skin. International journal of pharmaceutics · 20 Apr 2026 PMID 42009147
- Long-term stability of insulin eye drops in three different vehicles. Journal of pharmaceutical sciences · 17 Apr 2026 PMID 41997424
- When the system fails: Barriers to type 1 diabetes medication access and the emergent role of social media support. Diabetic medicine : a journal of the British Diabetic Association · 17 Apr 2026 PMID 41996632
- Exploring the Holdase Activity of Supramolecular Chaperones with Amyloid-Forming Peptides and Insulin. Biomacromolecules · 16 Apr 2026 PMID 41988752
Preclinical: animal, cell and lab studies (6)
- Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. The AAPS journal · 29 Jun 2026 PMID 42373916
- Vagal activation inhibits insulin release through neuronal nitric oxide synthase in obese male mice. Science signaling · 26 May 2026 PMID 42189938
- pH-Responsive Injectable Polyethylene Glycol and Dopamine-Grafted Chitosan Hydrogel for Sustained Insulin Release for Better Diabetic Treatment. ACS applied bio materials · 18 May 2026 PMID 42148601
- FEA-guided co-design of bubble microneedles: controlled tip separation for rapid transdermal and sublingual delivery. Drug delivery · 12 May 2026 PMID 42118678
- Analyses of Individual Singly Charged Ions Using a High-Field Orbitrap Analyzer. Analytical chemistry · 12 May 2026 PMID 42117381
- Combination amino acids and glucose effects on insulin and GLP-1 secretion. The Biochemical journal · 22 Apr 2026 PMID 42017410
Unclassified: not yet indexed with MeSH (2)
- Assessment of alpelisib-induced hyperglycemia in a real-world setting: A nationwide claims data analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 20 May 2026 PMID 42159385
- Pharmacological treatment patterns, factors associated with glycemic control, and renal function parameters in a real-world cohort of Hispanic adults with type 2 diabetes. Biomedical reports · 16 Apr 2026 PMID 41987878
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-06-13. Last written: 2026-08-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.